The Role of Circulating Tumor (ct)DNA Testing/Monitoring in Stage II-III Colorectal Cancer
EP. 1: Treatment Approach for Stage II/III Resectable CRC
Sepideh Gholami, MD, FACS, UC Davis Comprehensive Cancer Center
Key opinion leaders discuss their approach for the treatment of patients with stage II/III resectable colorectal cancer (CRC), with special consideration of factors for choosing perioperative therapy and the management of low- vs high-risk patients.
EP. 2: Role of ctDNA Testing/Monitoring in Early-Stage CRC
Sepideh Gholami, MD, FACS, UC Davis Comprehensive Cancer Center
A discussion on the evolving role of ctDNA (circulating tumor DNA) testing and monitoring in early-stage colorectal cancer (CRC).
EP. 3: ctDNA Monitorization Length and Clinical Experience
Sepideh Gholami, MD, FACS, UC Davis Comprehensive Cancer Center
Experts in the management of colorectal cancer (CRC) consider how long patients with early stage disease should receive ctDNA (circulating tumor DNA) monitorization, and provide insight into their personal experience using ctDNA testing.
EP. 4: ASCO GI 2021: Circulating Tumor DNA Analysis Data
Sepideh Gholami, MD, FACS, UC Davis Comprehensive Cancer Center
An overview of data presented at the ASCO GI (American Society of Clinical Oncology Gastrointestinal) 2021 Annual Meeting, regarding the circulating tumor DNA for assessment of recurrence risk, benefit of adjuvant therapy, and early relapse detection after treatment of patients with colorectal cancer (CRC).
EP. 5: ASCO GI 2021: MRD Detection With ctDNA From Assays
Sepideh Gholami, MD, FACS, UC Davis Comprehensive Cancer Center
Expert physicians discuss data presented at the ASCO GI (American Society of Clinical Oncology Gastrointestinal Cancers Symposium) 2021 annual meeting, regarding minimal residual disease (MRD) detection with ctDNA (circulating tumor DNA) from personalized assays in stage II and III patients with colorectal cancer.
